Grace Therapeutics, Inc. GRCE 深 滬
已收盤 05-22 16:00:00 美东时间
2.20
-0.040
-1.79%
華盛通- 最 高2.30
- 今 開2.25
- 成交量 25.98万股
- 最 低 2.18
- 昨 收 2.24
- 總市值 3404.29万
- 52周最高 5.18
- 市盈率 靜 --
- 換手率 1.68%
- 52周最低 1.79
- 委 比 99.81%
- 總股本 1547.40万
- 歷史最高 2016.00
- 量 比 0.91
- 振 幅 5.36%
- 歷史最低 1.75
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Required; Intends To Resubmit Application Following Resolution Of Cited Items
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical DataCompany Intends to Resubmit
04-24 01:17
Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safety Trial For Presentation At 2026 American Academy of Neurology Meeting, April 18-22
The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:Session: S21: Neurocritical CareDate: April 21,
04-14 20:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.28) by 50 percent. This is a 61.11 percent increase over losses of $(0.36) per share from
02-12 21:11
Grace Therapeutics Q2 EPS $(0.06) Beats $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.18) by 67.57 percent. This is a 80 percent increase over losses of $(0.30) per share from
2025-11-13 21:12
Grace Therapeutics Secures $4M Through Warrant Exercise
Grace Therapeutics ( ($GRCE) ) has shared an update. On October 23, 2025, Grace...
2025-10-23 20:28
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
Grace Therapeutics, Inc. has secured $4 million in additional funding through the exercise of common warrants issued in a 2023 private placement to support its lead drug candidate, GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The U.S. FDA has set a PDUFA target date of April 23, 2026, for reviewing the Company's NDA for GTx-104. aSAH is a rare and severe type of stroke caused by brain aneur...
2025-10-23 12:00
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
Grace Therapeutics announced positive results from its Phase 3 STRIVE-ON trial for GTx-104, an intravenous nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The trial showed GTx-104 is safe, reduces hypotension compared to oral nimodipine, and improves ICU outcomes. The FDA has accepted the NDA for review with a decision targeted by April 2026. The company highlights GTx-104's potential as a significant innovation for...
2025-09-22 12:00
Grace Therapeutics Secures New Patent for GTx-104
An update from Grace Therapeutics ( ($GRCE) ) is now available. On September 18...
2025-09-18 20:58
